Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non–small-cell lung cancer in CheckMate 227
JR Brahmer, JS Lee, TE Ciuleanu… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic …
Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study
S Gettinger, L Horn, D Jackman, D Spigel… - Journal of Clinical …, 2018 - ascopubs.org
Purpose In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor
antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non …
antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non …
First-line nivolumab plus ipilimumab in advanced non–small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational …
N Ready, MD Hellmann, MM Awad… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and
safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic …
safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic …
[HTML][HTML] First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer …
M Reck, TE Ciuleanu, M Cobo, M Schenker… - ESMO open, 2021 - Elsevier
Background To further characterize survival benefit with first-line nivolumab plus ipilimumab
with two cycles of chemotherapy versus chemotherapy alone, we report updated data from …
with two cycles of chemotherapy versus chemotherapy alone, we report updated data from …
First-line (1L) nivolumab (NIVO)+ ipilimumab (IPI)+ 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell …
LG Paz-Ares, TE Ciuleanu, M Cobo-Dols, J Bennouna… - 2022 - ascopubs.org
LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO+ IPI combined with 2
cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic …
cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic …
Nivolumab+ ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate …
SS Ramalingam, TE Ciuleanu, A Pluzanski, JS Lee… - 2020 - ascopubs.org
9500 Background: In the phase 3 CheckMate 227 Part 1 (NCT02477826; minimum follow-
up, 29.3 mo), 1L NIVO+ IPI significantly improved overall survival (OS) vs chemo in treatment …
up, 29.3 mo), 1L NIVO+ IPI significantly improved overall survival (OS) vs chemo in treatment …
[HTML][HTML] Nivolumab plus ipilimumab in advanced non–small-cell lung cancer
MD Hellmann, L Paz-Ares… - … England Journal of …, 2019 - Mass Medical Soc
Background In an early-phase study involving patients with advanced non–small-cell lung
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …
cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with …
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update …
LG Paz-Ares, TE Ciuleanu, JS Lee, L Urban… - 2021 - ascopubs.org
9016 Background: 1L NIVO+ IPI was shown to provide durable long-term overall survival
(OS) benefit vs chemo regardless of tumor programmed death ligand 1 (PD-L1) expression …
(OS) benefit vs chemo regardless of tumor programmed death ligand 1 (PD-L1) expression …
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international …
L Paz-Ares, TE Ciuleanu, M Cobo, M Schenker… - The Lancet …, 2021 - thelancet.com
Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate …
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
MD Hellmann, NA Rizvi, JW Goldman… - The lancet …, 2017 - thelancet.com
Background Nivolumab has shown improved survival in the treatment of advanced non-
small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the …
small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the …